-

JSR Life Sciences Company KBI Biopharma, Inc. Promotes Dirk Lange to CEO

DURHAM, N.C.--(BUSINESS WIRE)--JSR Life Sciences, LLC announced today that Dirk Lange will take over as president and chief executive officer of KBI Biopharma, Inc., a leading contract development and manufacturing organization (CDMO) and JSR Life Sciences affiliate company. Lange will be responsible for setting KBI’s global vision, defining strategic priorities and ensuring KBI’s continuous focus on quality and innovation.

Lange will report to JSR Life Sciences President Tim Lowery who also serves as an officer of JSR Corporation and chairman of the KBI Biopharma board of directors.

“Dirk’s deep industry experience and understanding of what makes KBI special, make him an ideal choice to take over the leadership role,” said Lowery. “I am confident in both his ability and his dedication to leading KBI.”

Lange has more than 20 years of experience in the biopharma industry, most recently serving as KBI’s chief operating officer. As COO, Lange oversaw operations at the company’s three US manufacturing locations and lead KBI’s transition from a clinical to a commercial manufacturing organization. He has also held management positions at Novartis in Switzerland, Sandoz in Austria and Rentschler Biopharma in Germany.

“Our collective vision is more compelling than ever, and I feel honored to serve as KBI’s CEO and grateful that we are a part of the JSR Life Sciences family,” said Lange. “Thanks to our world-class teams, we will continue our history of enabling clients to realize their vision and take ideas to treatments. I’m excited to build on our client-focused culture and expand our reach so that, ultimately, we empower the best of biopharma to tackle disease and restore health for patients in need.”

Approaching 1000 employees in the US and Europe, KBI is built upon a foundation of analytical capabilities, delivering efficient process development, clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy technologies.

About JSR Life Sciences, LLC

JSR Life Sciences, LLC is committed to the advancement of human health worldwide as a strategic partner to companies that discover, develop and deliver products to treat disease and improve the quality of life for patients. Based in Sunnyvale, CA, JSR Life Sciences operates a network of manufacturing facilities, R&D labs and sales offices. The JSR Life Sciences family of companies includes Crown Bioscience, KBI Biopharma, Inc., Medical & Biological Laboratories Co., LTD., Selexis SA and other affiliates throughout Europe and the Asia-Pacific region.

About KBI Biopharma, Inc.

KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of our 300+ client partners, we have worked closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. We have locations in Durham and Research Triangle Park (NC), Boulder and Louisville (CO), The Woodlands (TX), San Diego (CA), and Leuven, Belgium. More information is available at www.kbibiopharma.com

Contacts

Missy Bindseil
JSR North America Holdings, Inc.
JSR Life Sciences, LLC
830-237-9527
mbindseil@jsr-nahq.com

JSR Life Sciences, LLC


Release Summary
JSR Life Sciences Company KBI Biopharma, Inc. Promotes Dirk Lange to CEO
Release Versions

Contacts

Missy Bindseil
JSR North America Holdings, Inc.
JSR Life Sciences, LLC
830-237-9527
mbindseil@jsr-nahq.com

More News From JSR Life Sciences, LLC

Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs Targeting Cancer and Autoimmune Diseases

SUNNYVALE, Calif.--(BUSINESS WIRE)--JSR Life Sciences, LLC (“JSR”) today announced that Similis Bio (“Similis”), its business unit focused on biosimilar development, has announced plans to enter into a partnership with Novel351k to co-develop three biosimilar programs that address a wide range of hard-to-treat diseases. Under the initial agreement, Similis will be responsible for cell line development, analytics, process development, and cGMP production, leading to pharmacokinetics/pharmacodyna...

Similis Bio Partners With Blau Farmaceutica to Co-Develop Four Biosimilar Programs

SUNNYVALE, Calif. & SÃO PAULO--(BUSINESS WIRE)--JSR Life Sciences, LLC (JSR) and Blau Farmaceutica (Blau) (public company in Brazil B3 – BLAU3) today announced that Similis Bio (“Similis”), its recently launched business unit focused on biosimilar development, has signed its first development and license agreement with Blau Farmacêutica (“Blau”). The agreement, Blau’s most recent move into the biosimilars market, is a multi-product and multi-year deal to develop products and licenses IP for fou...

JSR Life Sciences Launches 'Similis Bio' to Help Partners Accelerate Biosimilar Development

SUNNYVALE, Calif.--(BUSINESS WIRE)--JSR Life Sciences, LLC (JSR) today announced the launch of a new business division, Similis Bio (Similis), which will operate a partnering program designed to help biopharmaceutical companies improve the efficiency and cost of biosimilar development. Similis will rely on core expertise in developing and manufacturing biologics to mitigate the challenges inherent in biosimilar drug development. Similis provides biosimilar drug developers with solutions designe...
Back to Newsroom